Abstract
Background
Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and invariably fatal neoplasm. Some studies have shown that cytoreductive surgery (CRS) combined with perioperative intraperitoneal chemotherapy (PIC) achieved an improved survival, as compared to historical controls. However, the significance of lymph node involvement in this disease has never been well defined.Methods
One hundred patients with DMPM underwent CRS and PIC at the Washington Hospital Center. The inclusion criteria for surgery consisted of histological diagnosis of DMPM, age <80 years and good performance status. All data were collected prospectively. Lymph node status, seven clinical variables and eight treatment-related prognostic factors were analyzed for survival.Results
Seven patients were lymph node positive and they all died of their disease within 2 years after the surgery. The remaining 93 patients had 5- and 7-year survival of 50% and 43%, respectively. Univariate analysis showed that gender (p<0.001), peritoneal cancer index (p=0.009), lymph node status (p<0.001), extra-abdominal invasion (p=0.026), histological type (p<0.001), intraoperative blood loss (p=0.035), completeness of cytoreduction (p<0.001), intraperitoneal chemotherapy regimen (p=0.041), and redo cytoreductive surgery (p=0.022) were significant for survival. Multivariate analysis demonstrated that female gender, lymph node metastasis not detected, epithelial type, and adequate cytoreduction were independently associated with an improved survival.Conclusions
CRS and PIC showed an improved survival for DMPM, as compared to historical controls. Lymph node status along with three other prognostic variables was significant in the multivariate analysis.References
Articles referenced by this article (30)
Epidemiology of malignant mesothelioma
1987
Primary malignant peritoneal mesothelioma. A report of seven cases and a review of the literature.
Arch Surg, (11):1477-1481 1990
MED: 2241560
New strategies are needed in diffuse malignant mesothelioma.
Cancer, (12):2969-2979 1992
MED: 1451080
Prognostic factors in diffuse malignant pleural mesothelioma. A study of 167 patients.
Chest, (1):159-162 1988
MED: 3335148
Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-1985.
J Clin Oncol, (1):147-153 1988
MED: 3335886
Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma.
J Cancer Res Clin Oncol, (7):547-550 1992
MED: 1624547
Malignant mesothelioma in south east England: clinicopathological experience of 272 cases.
Thorax, (6):507-512 1997
MED: 9227715
Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma.
J Surg Oncol, (1):6-12 1999
MED: 9989414
Results of treatment of 33 patients with peritoneal mesothelioma.
Br J Surg, (11):1587-1593 2000
MED: 11091251
Show 10 more references (10 of 30)
Citations & impact
Impact metrics
Article citations
Impact of Perioperative Systemic Chemotherapy on Survival for Patients Who have Diffuse Malignant Peritoneal Mesothelioma Treated with CRS-HIPEC.
Ann Surg Oncol, 31(1):556-566, 08 Nov 2023
Cited by: 2 articles | PMID: 37940804
2022 PSOGI Consensus on HIPEC Regimens for Peritoneal Malignancies: Diffuse Malignant Peritoneal Mesothelioma.
Ann Surg Oncol, 30(12):7803-7813, 23 Jul 2023
Cited by: 1 article | PMID: 37481492
Peritoneal Mesothelioma: Systematic Review of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Protocol Outcomes.
Indian J Surg Oncol, 14(suppl 1):39-59, 04 Mar 2023
Cited by: 0 articles | PMID: 37359920 | PMCID: PMC10284774
Review Free full text in Europe PMC
Diagnostic and Therapeutic Pathway in Diffuse Malignant Peritoneal Mesothelioma.
Cancers (Basel), 15(3):662, 21 Jan 2023
Cited by: 4 articles | PMID: 36765620 | PMCID: PMC9913096
Review Free full text in Europe PMC
Selection Factors for Treatment and Stratification of Rare Abdominal or Pelvic Tumors with Peritoneal Metastases.
Indian J Surg Oncol, 14(suppl 1):7-14, 30 Jul 2022
Cited by: 3 articles | PMID: 37359915 | PMCID: PMC10284755
Review Free full text in Europe PMC
Go to all (41) article citations
Similar Articles
To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.
Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma.
Ann Surg Oncol, 14(1):41-49, 13 Oct 2006
Cited by: 84 articles | PMID: 17039392
Lymph node metastases in diffuse malignant peritoneal mesothelioma.
Ann Surg Oncol, 17(1):45-53, 24 Oct 2009
Cited by: 38 articles | PMID: 19856030
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.
J Clin Oncol, 27(36):6237-6242, 16 Nov 2009
Cited by: 325 articles | PMID: 19917862
Comprehensive management of diffuse malignant peritoneal mesothelioma.
Eur J Surg Oncol, 32(6):686-691, 18 Apr 2006
Cited by: 73 articles | PMID: 16621431
Review